Minimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
|
|
- Rose Walsh
- 6 years ago
- Views:
Transcription
1 Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
2 1. The logistics of MRD assessment in AML 2. The clinical significance of MRD 3. MPFC for MRD detection 4. The choice of tissue for MRD determination in remission 5. Clinical trials aimed at eradicating or preventing MRD 6. Perspectives
3 1. The logistics of MRD assessment in AML The achievement of (CR) is a prerequisite for cure in AML. CR, based on the morphologic recognition of 5% of leukemic blasts in the BM, does not provide sufficient insight into the quality of the response. Despite CR rates of 50%-80% (depending on age), relapse within 3-5 years from diagnosis. Therefore, there is great need of more sensitive prognostic factors that can predict relapse
4 MRD MRD defined as any measurable disease or leukemia detectable above a certain threshold (defined by the methodology applied), predicts failure to maintain a morphologic CR and affects survival negatively
5 The MRD concept. x-axis represents time; y-axis represents tumor burden. The MRD concept. x-axis represents time; y-axis represents tumor burden. The horizontal black line represents the sensitivity of standard morphologic analyses, such as light microscopy using immunohistochemical methods. I, II, and III indicate 3 different courses of disease documented by MRD measurements. Patient course I (early relapse) can be distinguished from II and III (late relapse and complete cytogenetic response, respectively) by MRD measurements during therapy (period A). Relapse (patient course I and II) can in some cases be identified several months before clinical symptoms by MRD measurements after discontinuation of therapy (period B) by American Society of Hematology Hokland P, and Ommen H B Blood 2011;117:
6 The detection of residual leukemic cells with techniques more sensitive and less subjective than morphology has added a new prognostic dimension to the treatment of AML. With few exceptions, 1- the integration of MRD has superseded standard risk classifications based on age, WBC count, and cytogenetic and genotypic features. 2. To date, MRD has rarely been used in the prospective risk stratification of AML patients, given that testing the clinical utility of MRD monitoring has been marred by inconsistencies in MRD thresholds, 3. uncertainty on the choice of the most informative MRD time points, 4. and the lack of standardized MRD assays. Therefore, clinical proof for improved outcome after MRD-directed therapy remains scarce.
7 The interactions between MRD and presenting prognostic features continue to reveal an unforeseen complexity. Whereas genetic features such as unfavorable cytogenetics and poor-risk gene mutations are among the factors associated with an increased frequency of MRD after therapy, MRD status adds independent prognostic information within these established risk categories.
8 2. The clinical significance of MRD Although rapid tumor clearance after therapy initiation is of critical value, some investigators have found that post consolidation MRD levels carry superior prognostic power. One relies on MRD detection early on, after induction therapy, to refine risk stratification, which otherwise relies mostly on pretreatment parameters.
9 Relapse rates in the 4 AML risk categories according to number of LAP cells in the first BM in mcr. High risk (MRD: greater than 10 2 LAP + cells); intermediate risk (MRD: 10 3 to 10 2 LAP + cells); low risk (MRD: fewer than 10 3 LAP + cells); and very low risk (fewer than 10 4 LAP + cells; none have had relapses San Miguel JFBlood. 2001;98:
10 Overall survival of patients with AML according to MRD levels San Miguel JFBlood. 2001;98:
11 Relapse rates of APL and non-apl patients with AML according to the MRD levels.high risk (MRD: greater than 10 2 LAP+ cells), intermediate risk (MRD: 10 3 to 10 2LAP+ cells), low risk (MRD: fewer than 10 3LAP+ cells); and very low risk (fewer than 10 4 LAP+... San Miguel J F et al. Blood 2001;98: by American Society of Hematology
12 Results of the AML02 multicentre trial. 232 patients with de-novo AML (n=206), therapy-related or MDSrelated AML (n=12), or MLL (n=14) were enrolled at eight centres. The primary aim of the study was to compare the incidence of MRD positivity of the high-dose group and the low-dose group at day 22 of induction 1. Induction 2 consisted of ADE with or without gemtuzumab ozogamicin (GO) consolidation therapy included three additional courses of chemotherapy or haematopoietic stem-cell transplantation (HSCT). Levels of MRD were used to allocate GO and to determine the timing of induction 2.
13 Cumulative incidence (CI) of relapse or induction failure according to minimal residual disease (MRD)(A) CI for patients who were positive or negative for MRD after Induction I. (B) CI for patients with negative, low, or high MRD after of Induction I. (C) CI for patients who were positive or negative for MRD after Induction II. (D) CI for patients with negative, low, or high MRD after Induction II.
14 According to these studies early evaluation of disease response may also be of particular interest in the context of novel, investigational agents. The other approach uses serial monitoring of MRD during hematologic remission in an effort to prevent the development of clinical relapse by reacting to increasing MRD levels with preemptive therapy.
15 The introduction of high-dose versus low-dose cytarabine did not significantly lower the rate of MRDpositivity after induction 1 (34%vs 42%,p=0.17). 80% (155 of 193) of patients achieved MRD of less than 0.1% after induction 2, and the cumulative incidence of relapse for this group was 17% (SE 3). MRD of 1% or higher after induction 1 was the only significant independent adverse prognostic factor for both event-free and overall survival Rubnitz J, Lancet Oncol. 2010;11:543
16 It is still a matter of debate what is the best method to use to measure of MRD. The various methods are compared based on their sensitivity and specificity, The chosen threshold determines both sensitivity and specificity of an MRD assay. MRD thresholds with prognostic relevance are highly dependent on methodology (molecular or immunophenotypic)
17 Using multi-color antibody (Ab) combinations, the limit of detection with multiparameter flow cytometry (MPFC) can reach 10-4 (0.01%) depending upon the leukemiaassociated immunophenotype (LAIP). used and sample quality, a level comparable to that achieved by RT-PCR methodology for measuring molecular targets. The few direct comparisons of the 2 methodologies published in AML have demonstrated that quantitation of molecular targets and MPFC were equally effective in identifying patients at high risk of relapse. Rossi G et al.leuk Res Apr;36(4): Perea G, Leukemia. 2006; 20(1):87-94.
18 Prognostic value of a 0.1% cutoff value of MRD assessed by FC in AML with t(8;21) and inv(16). Cumulative incidence of relapse according to MRD detected by FC at the end of chemotherapy Prognostic value of a 410 copies cutoff value of MRD assessed by RQ-PCR in AML with t(8;21) and inv(16). Cumulative incidence of relapse according to MRD detected by RQ-PCR at the end of treatment. Perea C et al Leukemia (2006) 20, 87 94
19 German-Austrian AML Study Group treatment trials To evaluate the prognostic impact of MRD in patients with AML expressing the CBFB- MYH11 fusion transcript. PCR was performed on 684 bone marrow (BM; n = 331) and/or peripheral blood (PB; n = 353) samples from 53 younger adult (16 to 60 years old) patients with AML treated in prospectively.
20 Graphical view of the minimal residual disease (MRD) checkpoints I, II, and III that allow the identification of patients at high risk of relapse. (B) Recommendation for sample collection with regard to the different checkpoints.
21 Kaplan-Meier survival estimates for patients with inv(16) according to their real-time quantitative reverse transcriptase polymerase chain reaction (PCR) status at checkpoints I (PCR negativity in bone marrow during consolidation) and II (at least two PCR-negative specimens in bone marrow and/or peripheral blood during consolidation and early * 3 months] follow-up). (A) Relapse-free survival (RFS) at checkpoint I. (B) RFS at checkpoint II. (C) Overall survival at checkpoint II. Using the standardized Europe Against Cancer quantitative RT-PCR protocol, CBF/ MYH11 copy ratios at diagnosis and after induction therapy did not affect outcome; however, achievement of MRD in at least 2 specimens during or up to 3 months after consolidation predicted for long-term remission.
22 Monitoring of CBFB-MYH11 transcript levels should be incorporated into future clinical trials to guide therapeutic decisions. Corbacıoglu A et al. J Clin Oncol. 2010;28(23):
23 Impact of additional karyotypic markers at diagnosis and after induction RT-PCR positively on relapse free survival.. (A) RFS in entire cohort. (B) CIR of patients who were RT-PCR-positive or -negative at the end of induction. (C) Event-free survival of patients who were RT-PCR positive or negative at the end of induction. (D) CIR among good risk cases (WBC < /Lt and platelet count > /Lt at diagnosis) of those who were RT-PCR positive or negative at the end of induction. (E) CIR among highrisk group (not fulfilling good risk criteria) who were RT-PCR positive or negative at the end of induction. (F) RFS among those who had and those who did not have an additional cytogenetic 2012 by American Society of Hematology Chendamarai E et al. Blood 2012;119:
24 After induction with single-agent ATO, any molecular MRD is associated with a risk of relapse. Therefore, the prognostic value of MRD needs to be assessed in the context of each therapy. Blood. 2012;119(15):
25 Subgroup analysis of RFS and CIR of 143 AML patients stratified according to pretreatment karyotype or FLT3 status and levels of MRD after consolidation. Subgroup analysis of RFS and CIR of 143 AML patients stratified according to pretreatment karyotype or FLT3 status and levels of MRD after consolidation. (A-B) Those with a level of residual leukemic cells < 0.035% are referred to as intermediate karyotype-mrd, favorable karyotype-mrd, or FLT-wt MRD, whereas those with levels 0.035% are categorized as intermediate karyotype-mrd +, favorable karyotype-mrd +, or FLT-wt MRD +. Survival outcomes of these subsets and of U-RK and FLT3-ITD category are shown (P <.001 for all comparisons). (C-D) FLT-wt patients achieving a MRD-negative status show a better outcome than those who remained MRDpositive after consolidation (P <.001) by American Society of Hematology Buccisano F et al. Blood 2012;119:
26 Sequential study of 138 patients during the clinical course showed that DNMT3A mutations were stable during AML evolution the DNMT3A mutation may be a potential biomarker for monitoring of MRD was an independent poor prognostic factor for OS and RFS (P <.001). Hou H et al. Blood 2012;119:
27 OS and RFS in total patients and in younger patients with CN-AML by American Society of Hematology Hou H et al. Blood 2012;119:
28 Changes in mutation status between presentation and relapse may limit the clinical applicability of these markers and prompts the search for new, more stable mutations, such as of DNMT3A. Clonal instability implies that gene mutations should be reestablished at the time of relapse, not only for the purpose of MRD determination but especially before continuing therapy targeting those mutations.
29 Next-generation sequencing (NGS) might be particularly useful for MRD targets like FLT3-ITD, which is plagued by mutational shifts between diagnosis and relapse By multi clonality at presentation leading to the outgrowth of a clone at relapse different from that dominant at diagnosis, and by variable insertion sites and lengths among patients. Chromosomes Cancer. 2012;51(7):
30 Increased sensitivity for MRD monitoring is particularly important post allogeneic hematopoietic stem cell transplantation (HSCT), when presence or rise in MRD is likely to be predictive of relapse. Especially in patients who lack specific molecular markers, quantitative analysis of chimerism (ratio of donor- to recipient-derived hematopoiesis) serves as a reliable indicator of imminent relapse, particularly if mixed chimerism is assessed in CD34 cells. Curr Hematol Malig Rep. 2010;5(3):
31 Chimerism-based pre-emptive intervention with azacitidine has been shown to substantially delay relapse, allowing for donor lymphocyte infusions or a second HSCT.
32 Variations in the kinetics of leukemic cells affect the usefulness of MRD monitoring for the detection of relapse and determine the frequency of optimal MRD assessments during CR. Due to variable, but generally faster, doubling times of the PML/RARA clone, more frequent sampling is necessary.
33 The growth rate of NPM1MUT, FLT3- ITD leukemic cells is double that of NPM1MUT/FLT3 wild-type blasts, suggesting that relapse kinetics in AML depend on the complex genetic makeup of individual patients.
34 3. MPFC for MRD detection The advantage of MPFC-based MRD-assays is that they determine accurately the number of leukemic majority of AML patients. With common methodologies, only approximately 50% of AML patients have a suitable molecular target. Levels chosen to distinguish MPFC MRD+ from MRD- patients range from 0.035%-1%, with most studies using 0.1%. Semin Oncol. 2008;35(4): Blood. 2001;98(6): Lancet Oncol. 2010;11(6): Leuk Res. 2012;36(4):
35 The potentially higher prognostic MRD threshold in AML has important implications: (1) sensitivities of current MPFC MRD assays suffice and (2) reducing MRD levels in AML to those significant prognostically in ALL may not be necessary for improved clinical outcome. One significant drawback of most prognostic MRD levels to date is that they were derived retrospectively without validation in prospective clinical trials. Blood. 2012;120(2):
36 The analysis of immunophenotypic aberrancies with MPFC as a measure of MRD presents with its own challenges 1. Comparisons of paired presentation/relapse samples often show selective LAIP changes. 2. Such immunophenotypic shifts will not affect the utility of MPFC for MRD detection, provided that as many independent LAIPs as possible are monitored per patient. This approach also reduces the likelihood of falsepositive MRD results due to the potential presence of LAIP Ag combinations at low frequencies in normal BM, BM after chemotherapy, or after growth factor administration.
37 Granted, depending on the expertise of the flow cytometry operator, Ag expression patterns may be misinterpreted. In this regard, standardized protocols and automated data file analyses may be particularly useful for MRD detection in AML., With cells acquired, a 20-cell cluster represents a sensitivity of 1 in 104 (0.01%). As a result, if the sample quantity is limited, the sensitivity of the MRD assay will be lowered. This stresses the importance of sample quality for accurate MRD evaluation.
38 Abs suitable for MRD detection (1) distinguish leukemic blasts from normal myeloid precursors; (2) detect lineage-foreign markers (eg, lymphoidaffiliated Ags such as CD7 and CD19), (3) detect altered density of myeloid or lineageuncommitted Ags compared with normal myeloid precursors (eg, CD33 and CD11a), or (4) detect asynchronous expression of Ags, (eg, CD123 and CD34).
39 Characteristic immunophenotypes that are associated with recurrent genetic lesions, also termed surrogate marker profiles allow a highly focused approach to MRD assessment (eg, CD19,CD11a,CD56/ AML1/ETO AML or CD2 CBF/MYH11 AML). Unfortunately, to date, reliable surrogate profiles are rare and do not comprise common gene mutations in AML, such as FLT3-ITD. NPM1MUT AML typically lacks CD34 and CD133 expression; this relationship between genotype and immunophenotype is useful for MRD testing, even if it is not found in all cases. The disappearance of characteristic Ag profiles at relapse could signify the loss of the defined molecular clones. Leukemia. 2012;26(6):
40 The persistence of LSCs after therapy and outgrow that relapse may explain treatment failure in MPFC-MRD AML, because routine MRD Ab panels fail to detect LSCs. Contained within the CD34 CD38 cell compartment, LSCs in AML, but not APL, differ from normal hematopoietic stem cells by high expression of several Ags, including CD123 and C- type lectin-like molecule-1 (CLL-1). Best Pract Res Clin Haematol. 2010;23(3):
41 4. The choice of tissue for MRD determination in remission Hemodilute BM aspirates yield lower MRD levels if the contaminating PB contains fewer residual blast cells. In APL, MRD conversion occurs earlier in the BM than in the PB.
42 For molecular MRD targets with slow relapse kinetics, such as CBF/MYH11 and NPM1MUT (only when FLT3- ITD), PB testing may suffice provided that MRD sampling is done frequently for the period in which most relapses occur.
43 Real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) analysis in paired bone marrow (BM) and peripheral blood (PB) samples obtained after induction therapy, during consolidation therapy, and during follow-up. Corbacioglu A et al. JCO 2010;28: by American Society of Clinical Oncology
44 In NPM1 MUT AML, MRD- results in PB despite continued MRD+ BM tests increase with prolonged therapy. With MPFC, the PB contains distinctly fewer residual blasts than BM at all time points. However, MRD information from the PB can have prognostic significance. Leukemia. 2010;24(9): Blood. 2012;119(2):
45 Despite lower sensitivity, MRD MPFC assays in PB have higher specificity due to the absence of normal immature myeloid cells, which can complicate MRD analysis in BM. With gene over expression as the MRD target, the normal physiologic background is lower in the PB than in the BM, thus interfering less with MRD interpretation. Blood. 2011;117(9):
46 The relationship between expression of an overexpressed MRD marker (eg, WT1) in PB and BM and MRD sensitivity in PB and BM. In the example in this figure, (BM MRD level/pb MRD level) = (BM physiologic level/pb physiologic level), making the 2 tissues equally useful. Hokland P, and Ommen H B Blood 2011;117: by American Society of Hematology
47 5. Clinical trials aimed at eradicating or preventing MRD In the pediatric AML02 trial, MRD levels did not differ whether induction included high- or low-dose cytarabine, being paralleled by similar relapse and survival parameters. In each treatment arm, the presence of high MRD ( 1%) was an independent adverse prognostic factor for survival Lancet Oncol. 2010;11(6):543-
48 The benefits of allogeneic HSCT in MRD+ pediatric patients or adult AML patients are questionable, even though a St Jude study suggested that improvements in HSCT over time have diminished the negative effects of MRD. Further reduction of MRD before transplantation in that study did not impact outcome, a finding that contrasts with observations in ALL Leung W et al. Blood 2012;120:
49 Survival and cumulative incidence of relapse after HCT stratified by MRD level. Leung W et al. Blood 2012;120: by American Society of Hematology
50 Current strategies in eliminating MRD are disappointingly limited. Clofarabine and cytarabine have been tested in pediatric AML patients in CR with MRD 0.1% (NCT ). This drug combination was used previously in adult AML (NCT ), although data on this are not yet available.
51 Cumulative incidence (CI) of relapse or induction failure according to minimal residual disease (MRD)(A) CI for patients who were positive or negative for MRD after Induction I. (B) CI for patients with negative, low, or high MRD after of Induction I. (C) CI for patients who were positive or negative for MRD after Induction II. (D) CI for patients with negative, low, or high MRD after Induction II. Lancet Oncol. 2010;11(6):543-
52 Novel therapies are needed to treat MRD AML after chemotherapy more successfully; for example, in the form of immunotherapy. Clin Dev Immunol. 2011;2011:104926
53 Two ongoing trials in adult AML are testing this hypothesis: 1. NCT is assessing the effects of maintenance therapy with histamine dihydrochloride (Ceplene) and 2. low-dose IL-2 on MRD and NCT (LAM07), which is being conducted by the PETHEMA Foundation, stratifies patients before first consolidation according to karyotype and molecular findings at presentation and 0.1% MRD at the end of induction. Similar in design to the pediatric AML02 trial, this is the first trial in adult AML that responds to MRD-positivity with targeted immunotherapy. Lancet Oncol. 2010;11(6):
54 Therapeutic vaccination with dendritic cells, which is intended to generate anti leukemic T- cell responses, is another investigational approach with great potential for eradicating MRD. Bull Cancer. 2012;99(6):
55 A randomized trial of epigenetic priming with the hypomethylating drug decitabine (NCT ) also holds promise. Preemptive therapy with the DNA-methylation inhibitor 5-azacytidine in NPM1MUT AML patients in molecular relapse yielded promising results. Haematologica. 2011;96(10):
56 MRD course of 7 patients with molecular response to single agent azacitidine. MRD course of 7 patients with molecular response to single agent azacitidine. Tx: date of allogeneic HSCT; R: hematologic relapse. MRD monitoring in bone marrow samples is represented by the continuous lines; dashed lines reflect MRD monitoring from peripheral blood samples by Ferrata Storti Foundation Sockel K et al. Haematologica 2011;96:
57 6. Perspectives In pediatric AML, MRD has been added to conventional risk stratifications, but not so in adult AML (with the exception of APL). Randomized trials assigning patients in morphologic CR to MRD-adapted treatment arms are a rarity rather than the normal. Recently, the National Cancer Institute (NCI) has initiated an effort to standardize MPFC-MRD measurements among the leukemia reference laboratories of the 3 adult cooperative groups. Although seemingly small, this is a step of the utmost importance in the right direction.
58 Theoretically, we could be ready to treat every patient with AML individually according to risk allocation, which must include MRD levels. This approach would intensify treatment or switch chemotherapy to an MRD-targeting strategy in MRD+ patients and reduce treatment intensity in MRDLOW/- patients.
MRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationReview Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
Review Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? Federico Mosna 1, *, Debora Capelli 2 and Michele Gottardi 3 1 Hematology and Bone Marrow Transplantation Unit, Ospedale
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationClinical Overview on Measurable Residual Disease (MRD) in Acute Myeloid Leukemia(AML)
Clinical Overview on Measurable Residual Disease (MRD) in Acute Myeloid Leukemia(AML) Konstanze Döhner Department of Internal Medicine III, University Hospital of Ulm, Ulm Germany DISCLOSURES OF COMMERCIAL
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationAcute Leukemia. Sebastian Giebel. Geneva 03/04/
Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012 www.ebmt.org Acute leukemias: EBMT survey 2 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant 2009 3 Acute leukemias: INCIDENCE
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationVUmc Basispresentatie
Clinical diagnostic cytometry Gerrit J Schuurhuis Dept of Hematology VU University Medical Center Amsterdam, Netherlands Use of immunophenotyping at diagnosis to trace residual disease after therapy 1.
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationAML Emerging Treatment Strategies
Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More information7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, Eva Lengfelder
Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines - A prospective multicenter
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationImpact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia
Impact of Biomarkers in the Management of Patients with Acute Myeloid Leukemia Hartmut Döhner Medical Director, Department of Internal Medicine III Director, Comprehensive Cancer Center Ulm Ulm University,
More informationMeasurable/Minimal Residual Disease in Patients with Acute Myeloid Leukemia Undergoing Transplantation
Measurable/Minimal Residual Disease in Patients with Acute Myeloid Leukemia Undergoing Transplantation June 9, 2018 Dave Sanford The Leukemia/Bone Marrow Transplant Program of British Columbia Disclosures
More informationGENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA
CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationEarly Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia
Early Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia Martha Arellano, MD 1 ; Suchita Pakkala, MD 1 ; Amelia Langston, MD 1 ; Mourad Tighiouart,
More informationPacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018 Outline Case study Introduction of Current management of infantile
More informationAML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More informationCARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital
CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationACUTE LYMPHOBLASTIC LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T
More informationMultiparameter flow cytometry can be used to
Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School
More informationTreatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
More informationAcute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities
Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationDana-Farber Cancer Institute, Boston, MA; 2 City of Hope National Medical Center, Duarte, CA; 3 Roswell Park Cancer Institute, Buffalo, NY; 4
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD) Andrew A.
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationNeue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)
Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin
More informationA pediatric patient with acute leukemia of ambiguous lineage with a NUP98-NSD1 rearrangement SH
A pediatric patient with acute leukemia of ambiguous lineage with a NUP98NSD1 rearrangement SH20170203 Rebecca LeemanNeill, Ronald Rice, Anita Malek, Patricia Raciti, Susan Hsiao, Mahesh Mansukhani, Bachir
More informationCytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Acute Myeloid Leukemia Articles Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Bruno C. Medeiros, 1 Megan Othus, 2,3 Min Fang, 3,4 Frederick R. Appelbaum,
More informationTHE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA. Ava Greco
THE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA Ava Greco REVIEW OF LITERATURE What is Leukemia? Abnormal growth of cells in the blood stream Progresses rapidly
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationTherapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328
Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328 Kenneth N. Holder, Leslie J. Greebon, Gopalrao Velagaleti, Hongxin Fan, Russell A. Higgins Initial Case: Clinical
More informationNUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow
Quality ID #67 (NQF 0377): Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow National Quality Strategy Domain: Effective Clinical Care
More informationPage: 1 of 12. Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Leukemia
Page: 1 of 12 Last Review Status/Date: September 2015 Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Description Treatment of acute myeloid leukemia (AML) is based upon risk stratification,
More informationMRD in AML: does it already guide therapy decision-making?
INFORMED DECISIONS IN ACUTE MYELOID LEUKEMIA: BEYOND MORPHOLOGY AND CYTOGENETICS MRD in AML: does it already guide therapy decision-making? Gert Ossenkoppele and Gerrit Jan Schuurhuis Department of Hematology,
More informationWhich is the best treatment for relapsed APL?
Which is the best treatment for relapsed APL? 7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, 2017 Eva Lengfelder Department of Hematology and Oncology University Hospital
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 19 Dec 2018 02:45:15 GMT) CTRI Number Last Modified On 25/12/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationBlast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome
RESEARCH ARTICLE Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome AJH Mrinal M. Patnaik, 1 Emnet A. Wassie, 1 Terra L. Lasho, 2 Curtis
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW
ADVANCES IN CHILDHOOD ACUTE LEUKEMIAS : GENERAL OVERVIEW Danièle SOMMELET European Scientific Seminar Luxemburg, 3.11.2009 1 Definition of acute leukemias Malignant process coming from lymphoid (85 %)
More informationKEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More informationRegulatory Aspects - AML & CLL
Regulatory Aspects - AML & CLL Dr Beatriz Flores November 2018 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationCharacteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies
Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies Sabine Kayser, * Julia Krzykalla, Michelle A. Elliott, Kelly Norsworthy, Patrick Gonzales,
More informationAcute myeloid leukemia: a comprehensive review and 2016 update
OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia
More informationClinical Overview: MRD in CLL. Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel
Clinical Overview: MRD in CLL Dr. Matthias Ritgen UKSH, Medizinische Klinik II, Campus Kiel m.ritgen@med2.uni-kiel.de Remission in CLL Clinical criteria (NCI->WHO) Lymphadenopathy Splenomegaly Hepatomegaly
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More information